Literature DB >> 6129508

Elimination of carcinoma cells from human bone marrow.

R Buckman, R A McIlhinney, V Shepherd, S Patel, R C Coombes, A M Neville.   

Abstract

The value of a monoclonal antibody, LICR-LON-Fib-75 (Fib-75), which mediates complement lysis and recognises an antigen present on all epithelial-tumour cells so far studied but not on lymphoid cells or bone-marrow stem cells, in clearing infiltrated bone marrow was assessed. Chromium-51-release and trypan-blue-exclusion assays showed that no tumour cells were viable after exposure to Fib-75 and complement except when large clumps (greater than 500 cells) were present, whereas Fib-75 had no significant effect on bone-marrow cells, as judged by colony-forming-unit and pluripotential-stem-cell assays.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129508     DOI: 10.1016/s0140-6736(82)91329-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy.

Authors:  M D Vincent; T J Powles; R C Coombes; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.

Authors:  J Timar; D P McIntosh; R Henry; A J Cumber; G D Parnell; A J Davies
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

4.  Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

Authors:  L Bjørge; S Junnikkala; E K Kristoffersen; J Hakulinen; R Matre; S Meri
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Antibody-dependent-cellular-cytotoxicity against cultured human breast cancer cells mediated by human effector cells using monoclonal and polyclonal antibodies.

Authors:  M E Gore; R A Skilton; R C Coombes
Journal:  Br J Cancer       Date:  1983-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.